New analysis helps guide use of erlotinib in advanced non-small cell lung cancer
April 18, 2012
Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd European Lung Cancer Conference in Geneva, Switzerland.
The results of biomarker analyses of a recently reported clinical trial confirm that patients with unknown or negative mutation status should be treated with the standard chemotherapy first, they say.
The TORCH trial was a randomized phase III trial conducted in Italy and Canada, which compared the efficacy of treatment with erlotinib, followed at progression of disease by cisplatin and gemcitabine, against the standard reverse sequence. Erlotinib is a drug that specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase.
The primary endpoint of the original TORCH study was overall survival and 900 patients were planned, however the study was stopped early as the first interim analysis showed that the erlotinib-first regimen was inferior to the standard approach.
In the new study, Dr Ming Tsao and colleagues conducted an exploratory analysis on the TORCH patient tumor samples that were available for analysis, looking for molecular biomarkers known to be potential predictors of benefit from EGFR inhibitors.
"Our results show a significant interaction in progression-free survival favoring treatment with erlotinib first in EGFR-mutated patients, and favouring first treatment with chemotherapy in EGFR wild type [non-mutated] patients," said Dr Tsao, from the Princess Margaret Hospital.
"However there was no significant interaction between treatment efficacy and overall survival. This shows that using erlotinib to treat patients with a mutated tumor is always effective, both in first and in second line; of course, it is much more convenient for these patients to receive it as first line, as shown also in other trials," Dr Tsao said.
Patients with EGFR mutations benefit from the erlotinib-first regimen because their tumors are very sensitive to the anti-tumor activity of the drug, he explained.
"The take-home message from this study is that in advanced non-small cell lung cancer patients, treatment with erlotinib first should only be applied to patients whose tumor is known to harbor EGFR mutation," said Dr Tsao. "Patients with unknown or negative mutation status should be treated with the standard chemotherapy first."
Commenting on the study which he was not involved in, Dr Tetsuya Mitsudomi from Aichi Cancer Center Hospital in Nagoya, Japan, member of the IASLC Board of Directors, said: "Many previous trials, for instance IPASS, NEJ002, WJTOG3405, OPTIMAL, EUROTAC, have already shown that EGFR mutation is the most reliable predictive marker for EGFR-TKI treatment. The current paper was able to confirm the importance of EGFR mutation testing when considering the use of erlotinib, especially in consideration of the far shorter progression-free survival obtained with erlotinib when the mutation was absent. Consequently, although it was thought that erlotinib is active even in lung cancer patients without EGFR mutation if compared with gefitinib, this study suggests that erlotinib should be avoided when treating patients without EGFR mutation, at least in the first-line setting."
This biomarker analysis was preplanned but actually only 36% of the samples could be anlayzed for EGFR mutation. This relatively low tissue accrual rate is precedented by many clinical trials in which the mutation analysis was performed retrospectively. "Therefore, we also have to consider prospective determination of oncogene mutation when we want to raise this rate such as in NEJ, WJTOG, OPTIMAL and EUROTAC," Dr Mitsudomi added.
"In summary, the TORCH-BIO study adds imprortant evidence to the research field of EGFR-TKI in lung cancer and emphazizes the importance of biomarker study for improvement of clinical outcome."
European Society for Medical Oncology
Related Erlotinib Current Events and Erlotinib News ArticlesSDSC/UCSD study uncovers mechanisms of cancer-causing mutations
Researchers at the San Diego Supercomputer Center (SDSC) and the Moores Cancer Center at the University of California, San Diego, have described for the first time the molecular mechanism of cancer development caused by well-known "resistance" mutations in the gene called epidermal growth factor receptor (EGFR). Blood samples as surrogates for tumor biopsies in patients with lung cancer
A study examined the feasibility of using circulating free DNA (cfDNA) from blood samples of patients with advanced non-small-cell lung cancer as a surrogate for tumor biopsies to determine tumor-causing epidermal growth factor receptor (EGFR) mutations and then correlate that with expected patient outcomes, according to a study published online by JAMA Oncology. Stereotactic body radiation therapy plus chemotherapy improves survival among stage 4 lung cancer patients
A clinical trial that combined stereotactic body radiation therapy with a specific chemotherapy regimen more than doubled survival rates for certain stage 4 lung cancer patients, UT Southwestern Medical Center cancer researchers report.Widely used osteoporosis drugs may prevent breast, lung and colon cancers
The most commonly used medications for osteoporosis worldwide, bisphosphonates, may also prevent certain kinds of lung, breast and colon cancers, according to two studies led by researchers at the Icahn School of Medicine at Mount Sinai and published today in the Proceedings of the National Academy of Sciences (PNAS). Kidney cancer patients respond well to a combination of 2 existing anti-cancer drugs
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs. Study May Explain Why Targeted Drug Doesn't Benefit Patients With Early-Stage Lung Cancer
The drug erlotinib is highly effective in treating advanced-stage lung cancer patients whose tumors have a particular gene change, but when the same drug is used for patients with early-stage tumors with the same gene change, they actually fare worse than if they took nothing. Drug-Target Database Lets Researchers Match Old Drugs to New Uses
There are thousands of drugs that silence many thousands of cancer-causing genetic abnormalities.Chemotherapy timing is key to success
MIT researchers have devised a novel cancer treatment that destroys tumor cells by first disarming their defenses, then hitting them with a lethal dose of DNA damage.Cancer stem cells linked to drug resistance
Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth.Immunotherapy data heralds new era of lung cancer treatment
A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.
More Erlotinib Current Events and Erlotinib News Articles
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain|
Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR). Despite initial responses, patients eventually progress by unknown mechanisms of “acquired” resistance.
Methods and Findings
We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain. Tumor cells from a sixth patient with a...
Erlotinib: Webster's Timeline History, 2003 - 2007|
by Icon Group International (Author)
Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Erlotinib," including when used in literature (e.g. all authors that might have Erlotinib in their name). As such, this book represents the largest compilation of timeline events associated with Erlotinib when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social sciences...
Erlotinib, gefitinib nip lung cancer mortality.(Pulmonary Medicine): An article from: Internal Medicine News|
by Erik L. Goldman (Author)
This digital document is an article from Internal Medicine News, published by International Medical News Group on September 1, 2004. The length of the article is 609 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Title: Erlotinib, gefitinib nip lung cancer mortality.(Pulmonary Medicine)
Author: Erik L. Goldman
Publication: Internal Medicine News (Magazine/Journal)
Date: September 1, 2004
Publisher: International Medical News Group
Volume: 37 Issue: 17 Page: 24(1)
Distributed by Thomson...
Erlotinib: An entry from Thomson Gale's Gale Encyclopedia of Cancer, 2nd ed.|
by Tish, A. M. Davidson (Author)
Students, researchers, and patients can find reliable, up-to-date and clearly written information in “The Gale Encyclopedia of Cancer,” a comprehensive survey of 120 cancers, cancer drugs, traditional and alternative treatments and diagnostic procedures.
Bevacizumab-erlotinib combo boosts lung cancer survival.(Pulmonary Medicine)(cancer medicine): An article from: Family Practice News|
by Jane Salodof MacNeil (Author)
This digital document is an article from Family Practice News, published by Thomson Gale on September 1, 2006. The length of the article is 713 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Title: Bevacizumab-erlotinib combo boosts lung cancer survival.(Pulmonary Medicine)(cancer medicine)
Author: Jane Salodof MacNeil
Publication: Family Practice News (Magazine/Journal)
Date: September 1, 2006
Publisher: Thomson Gale
Volume: 36 Issue: 17 Page: 43(1)
Distributed by Thomson...
Physicians' Cancer Chemotherapy Drug Manual 2015|
by Edward Chu (Author), Vincent T. DeVita Jr. (Author)
Completely revised and updated for 2015, the Physicians’ Cancer Chemotherapy Drug Manual is an up-to-date guide to the latest information on standard therapy and recent advances in the field. Written by world-class experts in clinical cancer therapeutics, this essential reference provides a complete, easy-to-use catalogue of over 100 drugs and commonly used drug regimens—both on- and off-label—for the treatment of all the major cancers. SPECIAL FEATURES: • Revised to reflect rapid advances in the field, incorporating treatment strategies and new drugs like afatinib, ceritinib, ibrutinib, idelalisib, obinutuzumab, and ramucirumab. • A specific chapter focused on profiling antiemetic drugs and antiemetic treatment regimens. • Diagrams of drug structures and pathways for many of...
2015 Oncology Nursing Drug Handbook|
by Gail M. Wilkes (Author), Margaret Barton-Burke (Author)
Written especially for nurses caring for patients with cancer, the 2015 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration. Completely revised and updated, the 2015 Oncology Nursing Drug Handbook includes a simplified chapter on molecular and biological targeted therapy that incorporates new information about immunotherapy, new indications, and the most important and common side effects. New drug entries include: afatinib, belinostat, ceritinib, ibrutinib, idelalisib,...
Protein Kinase Inhibitors in Research and Medicine, Volume 548 (Methods in Enzymology)|
by Kevan M Shokat (Editor)
This new volume of Methods in Enzymology continues the legacy of this premier serial with quality chapters authored by leaders in the field. This volume covers protein kinase inhibitors in research and medicine, and includes chapters on such topics as fragment-based screening, broad kinome profiling of kinase inhibitors, and designing drug-resistant kinase alleles.Continues the legacy of this premier serial with quality chapters authored by leaders in the field Covers research methods in biomineralization scienceContains sections focusing on protein kinase inhibitors in research and medicine
Handbook of Targeted Cancer Therapy|
by Daniel D. Karp (Author), Gerald S. Falchook MD MS (Author)
Make optimal use of the latest personalized therapeutic strategies with Handbook of Targeted Cancer Therapy! This concise, practical oncology reference examines more than 120 targeted therapy agents for which clinical trial data are available, and explains when and how you can use them to most effectively combat cancer.
Approach clinical challenges from any direction with separate sections on Targets by Organ Site, Carcinogenesis from the Perspective of Targeted Therapy, Molecular Targets and Pathways, and Targeted Therapy Agents.Find information easily thanks to a color-coded format and an intuitive organization.Access the complete contents online and on mobile devices, with regular updates to include newly approved treatments.Important state of the art cancer information for...
Genetic screening boosted survival in NSCLC.(Pulmonary Medicine)(non-small cell lung cancer)(Clinical report): An article from: Internal Medicine News|
by Jane Salodof Macneil (Author)
This digital document is an article from Internal Medicine News, published by International Medical News Group on October 15, 2008. The length of the article is 647 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.
Title: Genetic screening boosted survival in NSCLC.(Pulmonary Medicine)(non-small cell lung cancer)(Clinical report)
Author: Jane Salodof Macneil
Publication: Internal Medicine News (Magazine/Journal)
Date: October 15, 2008
Publisher: International Medical News Group
Volume: 41 Issue: 20 Page: 22(1)
Article Type: Clinical report
Distributed by Gale, a part of Cengage...